2023-10-31
Analysts lower expectations as tools giants blame declining bioproduction orders, reduced spending by smaller biotechs, and China’s economic slowdown.Workers at Thermo Fisher scientific’s viral vector safety facility in Cambridge, MA. Marc N. Casper, Thermo Fisher’s chairman, president and CEO, cited a lack of growth in bioproduction orders, increased reluctance by customers to spend on drug and vaccine development, and shrinking revenue in China due to slowing economic activity as factors in